Artificial intelligence in predicting postoperative heterotopic ossification following anterior cervical disc replacement
European Spine Journal · 2024
DOI: 10.1007/s00586-024-08396-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Spine Journal, 2024. Verfasst von Rui Zong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China. Hauptthemen laut MEDLINE: Ossification, Heterotopic, Total Disc Replacement, Cervical Vertebrae, Artificial Intelligence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Cadre Health Research Project of Sichuan Province, National Natural Science Foundation of China, 1.3.5 project for Postdoctoral Foundation of West China Hospital of Sichuan University.
Abstract (Originalsprache)
OBJECTIVE: This study aimed to develop and validate a machine learning (ML) model to predict high-grade heterotopic ossification (HO) following Anterior cervical disc replacement (ACDR). METHODS: Retrospective review of prospectively collected data of patients undergoing ACDR or hybrid surgery (HS) at a quaternary referral medical center was performed. Patients diagnosed as C3-7 single- or multi-level cervical disc degeneration disease with > 2 years of follow-up and complete pre- and postoperative radiological imaging were included. An ML-based algorithm was developed to predict high grade HO based on perioperative demographic, clinical, and radiographic parameters. Furthermore, model performance was evaluated according to discrimination and overall performance. RESULTS: In total, 339 ACDR segments were included (61.65% female, mean age 45.65 ± 8.03 years). Over 45.65 ± 8.03 months of follow-up, 48 (14.16%) segments developed high grade HO. The model demonstrated good discrimination and overall performance according to precision (High grade HO: 0.71 ± 0.01, none-low grade HO: 0.85 ± 0.02), recall (High grade HO: 0.68 ± 0.03, none-low grade HO: 0.87 ± 0.01), F1-score (High grade HO: 0.69 ± 0.02, none-low grade HO: 0.86 ± 0.01), and AUC (0.78 ± 0.08), with lower prosthesis‑endplate depth ratio, higher height change, male, and lower postoperative-shell ROM identified as the most important predictive features. CONCLUSION: Through an ML approach, the model identified risk factors and predicted development of high grade HO following ACDR with good discrimination and overall performance. By addressing the shortcomings of traditional statistics and adopting a new logical approach, ML techniques can support discovery, clinical decision-making, and intraoperative techniques better.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China.
- Department of Orthopaedic Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Xiang, Chengdu, Sichuan, 610041, China. dr.liuhao6304@hotmail.com.
Förderung
- Cadre Health Research Project of Sichuan Province
- National Natural Science Foundation of China
- 1.3.5 project for Postdoctoral Foundation of West China Hospital of Sichuan University
Zitieren
APA
Zong, R., Guo, C., He, J. B., Wu, T. K., & Liu, H. (2024). Artificial intelligence in predicting postoperative heterotopic ossification following anterior cervical disc replacement. European Spine Journal. https://doi.org/10.1007/s00586-024-08396-2
Vancouver
Zong R, Guo C, He JB, Wu TK, Liu H. Artificial intelligence in predicting postoperative heterotopic ossification following anterior cervical disc replacement. European Spine Journal. 2024. doi:10.1007/s00586-024-08396-2
BibTeX
@article{Zong2024,
author = {Zong, Rui and Guo, Can and He, Jun-Bo and Wu, Ting-Kui and Liu, Hao},
title = {Artificial intelligence in predicting postoperative heterotopic ossification following anterior cervical disc replacement},
journal = {European Spine Journal},
year = {2024},
doi = {10.1007/s00586-024-08396-2}
}
EUVIMED